Silence Therapeutics (SLNCF, $0.97) was a top loser over the last three months, falling -3 to $0.97 per share. A.I.dvisor analyzed 843 stocks in the Biotechnology Industry for the 3-month period ending May 1, 2025, and found that of them (2) exhibited an Uptrend while of them (7) demonstrated a Downtrend.